Cardiac natriuretic peptides: Contributors to cardiac cachexia or possible anti-obesity agents or both?

Diabetes

Volumn 61, Issue 10, 2012, Pages 2403-2404

  Costello Boerrigter, Lisa C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIOBESITY AGENT; GHRELIN; NATRIURETIC FACTOR;

BARIATRIC SURGERY; BIOGENESIS; BODY MASS; BODY WEIGHT; BROWN ADIPOSE TISSUE; CACHEXIA; CALORIC INTAKE; CATABOLISM; DOUBLE BLIND PROCEDURE; ENERGY EXPENDITURE; GENETIC ASSOCIATION; GENOTYPE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; IMMUNOREACTIVITY; INCIDENCE; INSULIN RESISTANCE; LIPOLYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; THERMOGENESIS; WHITE ADIPOSE TISSUE; WILD TYPE;

GHRELIN; HUMANS; HUNGER; MALE; NATRIURETIC PEPTIDE, BRAIN; SATIATION;

EID: 84866634824     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0763     Document Type: Note

References (21)

1. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 2011;130:71-82
2. Vila G, Grimm G, Resl M, et al. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes 2012;61:2592-2596
3. Khan AM, Cheng S, Magnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 2011;96:3242-3249
4. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007;115:1345-1353 (Pubitemid 46648370)
5. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006;152:1071-1076 (Pubitemid 44854793)
6. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600 (Pubitemid 38198866)
7. Chen-Tournoux A, Khan AM, Baggish AL, et al. Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. Am J Cardiol 2010;106:1450-1455
8. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000;14:1345-1351 (Pubitemid 30439743)
9. Sengenès C, Bouloumie A, Hauner H, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 2003;278:48617-48626 (Pubitemid 41079500)
10. Birkenfeld AL, Budziarek P, Boschmann M, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 2008;57:3199-3204
11. Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/ cGMPdependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009;58:2880-2892
12. Bordicchia M, Liu D, Amri EZ, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012;122:1022-1036
13. Meirhaeghe A, Sandhu MS, McCarthy MI, et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 2007;16:1343-1350 (Pubitemid 47055130)
14. Magnusson M, Jujic A, Hedblad B, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab 2012;97:638-645
15. Cannone V, Boerrigter G, Cataliotti A, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 2011;58:629-636
16. Heinisch BB, Vila G, Resl M, et al. B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebocontrolled cross-over study in healthy men. Diabetologia 2012;55:1400-1405
17. Welsh P, McMurray JJ. B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia 2012;55:1240-1243
18. Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009;53:2070-2077
19. Dries DL, Ky B, Wu AH, Rame JE, Putt ME, Cappola TP. Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ Heart Fail 2010;3:220-227
20. Niederkofler EE, Kiernan UA, O'Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-264
21. Addisu A, Gower WR Jr, Landon CS, Dietz JR. B-type natriuretic peptide decreases gastric emptying and absorption. Exp Biol Med (Maywood) 2008;233:475-482 (Pubitemid 351469304)